Inhibition of ras by farnesylthiosalicylate significantly reduces the levels of autoantibodies in two animal models of the antiphospholipid syndrome

Immunobiology

Volumn 207, Issue 1, 2003, Pages 47-50

  Katzav, Aviva ^a   Kloog, Yoel ^a   Korczyn, Amos D ^a   Molina, Vered ^b   Blank, Miri ^b   Shoenfeld, Yehuda ^b   Chapman, Joab ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CELL ANTIBODY; DNA ANTIBODY; DOUBLE STRANDED DNA; FARNESYLTHIOSALICYLIC ACID; FREUND ADJUVANT; HISTONE ANTIBODY; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLSERINE; PHOSPHOLIPID ANTIBODY; RAS PROTEIN; SINGLE STRANDED DNA; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC MODEL; IMMUNIZATION; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION;

EID: 0037214776     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1078/0171-2985-00208     Document Type: Article

References (10)

1. Pastor, M. I., K. Reif, and D. Cantrell. 1995. The regulation and function of p21ras during T-cell activation and growth. Immunol. Today 16: 159.
2. Aharonson, Z., M. Gana-Weisz, T. Varsano, R. Haklai, D. Marciano, and Y. Kloog. 1998. Stringent structural requirements for anti-Ras activity of S-prenyl analogues. Biochim. Biophys. Acta. 1406: 40.
3. Katzav, A., Y. Kloog, A. D. Korczyn, H. Niv, D. M. Karussis, N. Wang, R. Rabinowitz, M. Blank, Y. Shoenfeld, and J. Chapman. 2001. Treatment of MRL/1pr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS). Clin. Exp. Immunol. 126: 570.
4. Karussis, D., O. Abramsky, N. Grigoriadis, J. Chapman, R. Mizrachi-Koll, H. Niv, and Y. Kloog. 2002. The Ras-pathway inhibitor, S-trans-trans-farnesylthiosalicylic acid, suppresses experimental allergic encephalomyelitis. J. Neuroimmunol. 120: 1.
5. Kafri, M., V. E. Drory, N. Wang, Y. Kloog, A. D. Korczyn, and J. Chapman. 2000. Treatment of experimental autoimmune neuritis by a Ras inhibitor, s-farnesylthiosalicylic acid (FTS). Ann. Neurol. 48: 122.
6. Alarcon-Segovia, D. 1988. Pathogenic potential of antiphospholipid antibodies. J. Rheumatol. 15: 890.
7. Katzav, A., C. G. Pick, A. D. Korczyn, E. Oest, M. Blank, Y. Shoenfeld, and J. Chapman. 2001. Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus 10: 496.
8. George, J., M. Blank, Y. Levy, P. Meroni, M. Damianovich, A. Tincani, and Y. Shoenfeld. 1998. Differential effects of anti-beta2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation 97: 900.
9. Jabs, D. A., R. C. Kuppers, A. M. Saboori, C. L. Burek, C. Enger, B. Lee, and R. A. Prendergast. 1994. Effects of early and late treatment with anti-CD4 monoclonal antibody on autoimmune disease in MRL/MP-1pr/1pr mice. Cell. Immunol. 154: 66.
10. Asanuma, Y., K. Nagai, M. Kato, H. Sugiura, and S. Kawai. 2002. Weekly pulse therapy of methotrexate improves survival compared with its daily administration in MRL/1pr mice. Eur. J. Pharmacol. 435: 253.